The Alzheimer’s Diagnostic Database
This database provides an overview of available CSF, genetic, and blood tests for Alzheimer’s Disease. Understanding how these tests perform and support early, accurate diagnoses is essential for patient care. Where possible, data is provided on how the tests compare to CEOI’s blood test performance standards.
Explore The Diagnostic Database
Select the test category you’re interested in to filter the database down to the relevant options for you. You can find more information on
Amyloid PET Sites here.
ARUP Laboratories: Phosphorylated tau 217a
p-tau217
C2N Diagnostics: PrecivityAD®
Aß42/40 Ratio, ApoE and Age
C2N Diagnostics: PrecivityAD2™
Aß42/40 Ratio and p-Tau217/np-Tau217 Ratio
C2N Diagnostics: PrecivityAD2™ + Precivity-ApoE™
Aß42/40 Ratio, pTau-217/T-Tau Ratio, ApoE Proteotype
C2N Diagnostics: PrecivityAD2™ reflex to Precivity-ApoE™
Aß42/40 Ratio, pTau-217/T-Tau Ratio + ApoE Proteotype (if PrecivityAD2™ APS2 test result is positive)
Fujirebio: Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio
pTau 217/β-Amyloid 1-42 Ratio
Labcorp: ATN Profile
Aß42/40 Ratio, pTau-181, NfL
Labcorp: Beta Amyloid 42/40 Ratio, Plasma
Aß42/40 Ratio
Labcorp: GFAP
GFAP
Labcorp: NfL
NfL
Labcorp: Phosphorylated Tau 181 (pTau-181)
pTau-181
Labcorp: Phosphorylated Tau 217 (pTau-217)
pTau-217
Lucent Diagnostics: LucentAD Complete
p-Tau 217, Aβ42/40, NfL, and GFAP
Lucent Diagnostics: LucentAD p-Tau 217a
p-Tau 217
Mayo Clinic Laboratories: p-Tau217a
p-Tau217
Mayo Clinic Laboratories: PrecivityAD
Aß42/40 Ratio, APOE
Mayo Clinic Laboratories: PrecivityAD2
Aß42/40 Ratio, pTau-217/T-Tau Ratio, APOE
Neurocode Labs: GFAP
GFAP
Neurocode Labs: NfL
NfL
Neurocode: ALZpath Dx: Plasma Phosphorylated Tau 217 (p-Tau 217)a
p-Tau 217
Quest Diagnostics: AD-Detect® Phosphorylated tau181(p-tau181)
pTau-181
Quest Diagnostics: AD-Detect™ (Aβ 42/40 and p-tau217)
Aβ 42/40 and p-Tau217
Quest Diagnostics: AD-Detect™ Beta-Amyloid 42/40 Ratio
Aβ 42/40
Quest Diagnostics: AD-Detect™ Phosphorylated tau217
p-Tau217
Quest Diagnostics: Aβ 42/40, p-tau217, and ApoE Evaluation
Aβ 42/40, p-Tau217, and ApoE Evaluation
Quest Diagnostics: NfL
NfL
Roche Diagnostics: Elecsys Phospho-Tau (181P) Plasma
pTau181
Athena Diagnostics: ADmark® Phospho-Tau/Total-Tau/A Beta42,Analysis and Interpretation
pTau-217, T-Tau, Aß42
Labcorp: AD Evaluation
Aß42, T-Tau, pTau-181
Labcorp: Beta Amyloid 42/40 Ratio
Aß42/40 Ratio
Mayo Clinic Laboratories: ADEVL: Alzheimer Disease Evaluation
Aß42, T-Tau, pTau-181
Mayo Clinic Laboratories: AMYR: Beta Amyloid Ratio (1-42/1-40)
Aß42/40 Ratio
Neurocode Labs: Aß42/40
Aß42
Quest Diagnostics: Admark
pTau-181, T-Tau, Aß42
Quest Diagnostics: Beta-Amyloid 42/40 Ratio
Aß42/40 Ratio
Quest Diagnostics: Beta-Amyloid 42/40 Ratio and Apolipoprotein E (APOE) Isoform Panel
Aß42/40 Ratio, APOE
Athena Diagnostics: ADmark® ApoE Genotype Analysis and Interpretation (Symptomatic)
APOE E2, E3, E4
C2N Diagnostics: Precivity-ApoE™
APOE Proteotype
Labcorp: APOE
APOE
Mayo Clinic Laboratories: APOEG Apolipoprotein E Genotyping, Blood
APOE
Quest Diagnostics: AD-Detect™ Apolipoprotein E (ApoE) Isoform
APOE, E2, E3, E4
Quest Diagnostics: Apolipoprotein E (APOE) Isoform
APOE E2, E3, E4
CEOi’s Approach to Collecting Performance Data for Select Blood Tests
Data Collection
Once data submissions were received, CEOi conducted an independent quality check. Each dataset in the database is clearly labeled with its source.
Quality Check
Once data submissions were received, CEOi conducted an independent quality check. Each dataset in the database is clearly labeled with its source.
Performance Standards
CEOi convened stakeholders from across industries to assess and recommend clear standards for blood tests – supporting a more simple and accurate diagnostic experience for patients. Read CEOi’s published standards here.
Contact Us
If you are interested in submitting your data to the Performance Standards Database, or have questions or comments on the existing data, please complete this form.
The Global CEO Initiative on Alzheimer’s Disease
CEOi, founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. It is convened by UsAgainstAlzheimer’s.
